Speaker Biographies

CAROLYN R. (“BO”) ALDIGÉ
Founder and Steering Committee Member, Quantitative Imaging Workshop

Carolyn Aldigé is founder and CEO of the Prevent Cancer Foundation®, a national nonprofit organization she started in 1985 in memory of her father. The Prevent Cancer Foundation® is one of the nation’s leading voluntary health organizations and the only US nonprofit organization focused solely on cancer prevention and early detection. Since 2004, Ms. Aldigé and the Prevent Cancer Foundation®—in cooperation with Foundation vice-chair and scientific director Dr. James Mulshine—have organized and hosted the Quantitative Imaging Workshop.

Ms. Aldigé has served on boards of directors/advisors of eight National Cancer Institute-designated Cancer Centers, including the top-ranked MD Anderson Cancer Center and Vanderbilt Ingram Cancer Center. She is a member of the boards of directors of Friends of Cancer Research and the Intercultural Cancer Council, the Council of Scientific Advisors of the American Association for Cancer Research, the Patient Advocate Advisory Board of Stand Up to Cancer, the External Advisory Board of the Thoracic Oncology Center at Mt. Sinai Medical Center and the Advisory Board of Project ECHO.

Her international work includes serving as chairman of the coalition Global Action for Cancer Patients, vice-chairman of the Global Lung Cancer Coalition, a member of the advisory board of the International Early Lung Cancer Action Program and a member of the board of directors of the International Society for Cancer Prevention.

A 1996 Washingtonian of the Year, Ms. Aldigé is the only individual to have won public service awards from the American Association for Cancer Research, the American Society of Clinical Oncology and the American Society of Preventive Oncology.

carolyn.aldige@preventcancer.org
Twitter: @preventcancer
LinkedIn: https://www.linkedin.com/company/prevent-cancer-foundation

MELINDA ALDRICH, PhD, MPH

Dr. Melinda Aldrich is an associate professor in the Department of Medicine (Division of Genetic Medicine) at Vanderbilt University Medical Center. She received her MPH in Epidemiology/Biostatistics and her PhD in Epidemiology from University of California, Berkeley. She completed a Genetic Epidemiology postdoctoral fellowship at University of California, San Francisco. Her work is focused on understanding genetic and non-genetic factors driving lung cancer disparities, and most recently her research has an emphasis on disparities in lung cancer screening. She uses large-scale electronic health records linked to DNA biobanks and epidemiologic cohorts to investigate lung cancer. She is an invited member of the US National Lung Cancer Roundtable Lung Cancer Screening Implementation Strategies Task Group. She was awarded the Vanderbilt 2020 Chancellor's Award for Research on Equity, Diversity and Inclusion.

melinda.aldrich@vumc.org
Twitter: @MelindaAldrich

RICARDO AVILA, MS
Steering Committee Member, Quantitative Imaging Workshop

Ricardo Avila is a computer scientist and CEO of Accumetra, Inc., a high-performance imaging services company focused on advancing the science of image-based decision making. Mr. Avila has extensive experience leading the development of health care applications in academic, government and commercial settings, including at Howard Hughes Medical Institute, GE Global Research, Kitware and the United States Department of Veterans Affairs. His main area of expertise is in the development of computer-aided detection algorithms for early lung cancer and the quantitative measurement of lung nodule size change over time. Throughout his career, he has contributed to several open science projects including major open source initiatives (VTK, ITK and OSEHRA) as well as Give-A-Scan, a patient donated and openly available CT scan database for accelerating lung cancer research. Mr. Avila received a master’s degree in computer science from the State University of New York at Stony Brook, specializing in 3D biomedical imaging and visualization.

rick.avila@accumetra.com
LinkedIn: www.linkedin.com/in/ricardo-avila-1687451
MARY BARTON, MD, MPP
Dr. Mary Barton oversees the development, use and maintenance of techniques National Committee for Quality Assurance (NCQA) uses to evaluate health care quality. She ensures the scientific integrity of NCQA measurement and research. She also leads NCQA in winning and executing health care quality measurement contracts for federal and state governments.

Prior to NCQA, Dr. Barton worked for the Agency for Healthcare Research and Quality (AHRQ), where she was the scientific director of the US Preventive Services Task Force (USPSTF). She supported and provided oversight for the methodological, evidence review and recommendation-making work of the USPSTF. Before joining AHRQ, Dr. Barton was an assistant professor at Harvard Medical School, where she performed clinical epidemiology and health services research related to cancer screening and prevention in terms of access, test performance and outcomes.

Dr. Barton trained in primary care internal medicine at Brigham and Women’s Hospital in Boston and completed a general medicine research fellowship at Harvard. She has a clinical interest in and has presented widely about the performance of the clinical breast examination, and she is a member of the American College of Physicians and the Society of General Internal Medicine.

barton@ncqa.org
Twitter: @mberry99
Linkedin: www.linkedin.com/in/mary-barton-md/

SPENCER CARRUCCIU, MPA
Spencer Carrucciu is vice president of Oxeon Venture Studio at Oxeon Partners, a leading investments, and company creation firm focused solely on the healthcare industry. Prior to Oxeon Partners, Mr. Carrucciu was a senior advisor at the Center for Medicare and Medicaid Innovation (CMMI). Mr. Carrucciu also previously served as the head of Data & Analytics at Cityblock Health, a provider organization focused on bringing high-quality physical, mental and social care to traditionally underserved populations. Earlier in his career, he served as the vice president of Product at Remedy Partners, the leading convener in Medicare’s Bundled Payment Care Improvement program. Mr. Carrucciu has an MPA from the Robert F. Wagner Graduate School of Public Service at New York University (NYU) and a BS from the NYU Stern School of Business.

spencer@oxeonventures.com
Twitter: @OxeonPartners
Linkedin: www.linkedin.com/in/spencer-carrucciu-93b56215

SHONTA CHAMBERS, MSW
Shonta Chambers transitioned back to the non-profit sector in 2014 by joining the Patient Advocate Foundation (PAF). She leads the development and execution of strategic initiatives to expand PAF’s approach to achieve health equity through community and national level partnership engagement and mobilization. These initiatives are designed to link limited income communities to resources to abate financial, logistical and social access to care barriers. Ms. Chambers brings to this role nearly 25 years of non-profit and public sector middle and senior level experience that spans public health, women’s health and behavioral health.

Additionally, she serves as the principal investigator as part of DP18-1808 Centers for Disease Control and Prevention’s National Networks to Reduce Cancer and Tobacco Related Disparities Cooperative Agreement. In this role, she administers the SelfMade Health Network a national network focused on reducing cancer and tobacco related disparities among populations with low socio-economic characteristics.

shonta.chambers@patientadvocate.org
Twitter: @Chambers_PAF
Linkedin: www.linkedin.com/in/shontachambers
SAMUEL CYKERT, MD

Dr. Samuel Cykert is a professor of medicine at the University of North Carolina – Chapel Hill (UNC-CH) in the Division of General Internal Medicine and Clinical Epidemiology and was founding director for the Program on Health and Clinical Informatics. He graduated from Indiana University School of Medicine with Highest Distinction and did his Internal Medicine Residency and General Medicine Faculty Fellowship at UNC.

He started his career as a solo practitioner in Alamance County and learned firsthand how real world issues led to variations in care. Combining his research training, his role as a founding member of the Greensboro Health Disparities Collaborative, and interest in health policy, Dr. Cykert has been heavily involved in projects that address cancer and chronic care management including the building of systems that address health care disparities. He has served as principal or co-principal investigator on several studies including the National Cancer Institute-sponsored Accountability for Cancer Care through Undoing Racism and Equity system change intervention and the American Cancer Society-sponsored, “Lung Cancer Surgery: Decisions Against Life Saving Care – The Intervention.” Dr. Cykert also led the North Carolina Collaborative in the Agency for Healthcare Research and Quality’s “EvidenceNow” Project. The North Carolina group engaged 219 primary care practices caring for over 600,000 adult patients who achieved significant cardiovascular disease risk reductions especially among rural Black patients in the “Stroke Belt” region of the state.

sean_cykert@med.unc.edu

SEAN FAIN, PhD

Dr. Sean Fain is professor and vice chair of research in the Department of Radiology at University of Iowa. He previously served as professor of Medical Physics, Radiology and Biomedical Engineering at the University of Wisconsin – Madison. He now directs the Functional Lung Imaging Laboratory in the Iowa Institute for Biomedical Imaging. His research develops quantitative imaging methods using magnetic resonance imaging (MRI) and CT. His research is highly translational, including leadership roles in multi-center imaging studies of asthma (Severe Asthma Research Program; The Great Lakes PrecISE Partnership), and industry collaborations (GE Healthcare, Xemed LLC, Polarean, Imbio LLC) to improve quantitative measures of lung disease. He is the physics chair of the of the CT Lung Density Biomarker Committee of the Quantitative Image Biomarkers Alliance (QIBA) and is working with the COPD Foundation on quantitative CT imaging biomarkers of airway remodeling and parenchymal density to improve phenotyping of obstructive lung disease.

sean-fain@uiowa.edu
Twitter: @bedilionfain
Linkedin: www.linkedin.com/in/sean-fain-887ab178/

LEE GAZOURIAN, MD, MS

Dr. Lee Gazourian is director of Quantitative Analysis and co-director of research at the Lahey Hospital & Medical Center. His primary research interests are to apply quantitative Computer Tomography imaging technology to the lung cancer screening and COPD patient populations. He is currently the principal investigator of a multi-center study utilizing the lung cancer screening cohorts at Lahey Hospital & Medical Center, Mount Auburn Hospital, Boston Medical Center and Baystate Medical Center. To date over 16,000 patients have been screened with over 40,000 total CT scans performed. His research focuses on objective assessments of the pulmonary and extra pulmonary manifestations of disease both at baseline and longitudinally. His group is currently evaluating the association between both quantitative and qualitative metrics, of emphysema, interstitial lung disease, coronary artery calcification, pulmonary vascular disease and body composition with clinical outcomes including cancer, hospitalizations and quality metrics including COPD/ILD screening, cardiovascular risk stratification, immunizations and smoking cessation.

Dr. Gazourian received his medical doctorate from Boston University School of Medicine and his pulmonary and critical care training at the combined Harvard program.

lee.gazourian@lahey.org
CORY GUSLAND, FSA, MAAA

**Cory Gusland** is a principal and consulting actuary with the Chicago office of Milliman. Mr. Gusland is focused on creating sustainable health care financing structures that promote value-based health care. His areas of expertise are alternative payment models, managed care, and provider sponsored health plans. Mr. Gusland has experience working across commercial, Medicare and Medicaid populations.

His current responsibilities include assisting healthcare providers and integrated delivery systems as they transition to risk bearing entities. Recent projects include but are not limited to the design and implementation of value-based payment models, review of payer provider shared savings contracts, capitation payment analysis, provider reimbursement benchmarking, health plan feasibility studies, and cost and utilization projections for healthcare providers. Mr. Gusland is also a Milliman thought leader on Medicare ACOs and participates heavily in firm-wide research. He has led recent Society of Actuary efforts in Medicare ACO education, as well as provider risk measurement research.

cory.gusland@milliman.com
LinkedIn: [www.linkedin.com/in/corygusland/](http://www.linkedin.com/in/corygusland/)

CHARLES (“CHUCK”) HATT, PhD

**Dr. Charles Hatt** is a director of research and senior scientist at Imbio LLC, as well as a research adjunct professor in the Department of Radiology at the University of Michigan. His primary research interests are in the development and application of quantitative imaging biomarkers. He is the principal investigator on multiple NIH grants related to quantitative image-based analysis of cardiac and pulmonary diseases, and is also the primary machine learning architect of multiple imaging biomarker software applications at Imbio.

carleshatt@imbio.com

CLAUDIA I. HENSCHKE, PhD, MD

**James L. Mulshine, MD, National Leadership Award Presenter and 2015 Recipient**

**Dr. Claudia Henschke** is a pioneer and leading expert in diagnostic radiology with more than 25 years of clinical and research experience with low-dose CT screening; and she has led the implementation of numerous city, state, national and international lung screening programs.

Since the start, in 1992, of the Early Lung Cancer Action Project (ELCAP) Dr. Henschke has worked on advancing the CT screening research of early lung disease, with a particular focus on lung cancer. ELCAP soon grew into an international program (I-ELCAP), and now she leads a collaborative and international group of distinguished physicians and scientists whose 75 institutions have, to date, screened over 85,000 people in 10 countries around the world for I-ELCAP.

In addition, the success of the I-ELCAP program led to another multi-national study, The Initiative for Early Lung Cancer Research on Treatment (IELCART), implemented in 2016 to assess the efficacy of various early lung cancer treatments.

Prior to joining the Icahn School of Medicine at Mount Sinai in 2010, Dr. Henschke trained at the Brigham and Women’s Hospital at Harvard Medical School as well as a faculty member at the Harvard Medical School and the Weill Cornell Medical College. She has authored over 400 peer-reviewed publications, two books, many scientific presentations, and has trained over 80 physician researchers. Dr. Henschke was awarded her MD from Howard University, her PhD in Mathematical Statistics and Computer Science from the University of Georgia, and received a BA and MS in Statistics from Southern Methodist University.

claudia.henschke@mountsinai.org
In partnership with American Lung Association

JONATHAN B. JAFFERY, MD, MS, MMM
Dr. Jonathan Jaffery is a faculty member in the Division of Nephrology within the Department of Medicine of the University of Wisconsin – Madison (UW). As chief population health officer at UW Health and president of the UW Health ACO, Dr. Jaffery provides strategic leadership for UW Health's transformation toward value-based care. Dr. Jaffery works to ensure UW Health provides access to high quality, affordable, equitable care and contributes to the health of the community. From 2008 to 2010, he served as the chief medical officer for the state of Wisconsin's Medicaid program. As a 2010 - 2011 Robert Wood Johnson Foundation Health Policy Fellow, Dr. Jaffery worked for the Senate Committee on Finance on a variety of issues relating to delivery system and payment reform, and he continues to focus on these areas in his UW Health leadership roles. Since 2018 he has served as a commissioner on the Medicare Payment Advisory Commission (MedPAC), a nonpartisan agency that provides the US Congress with analysis and policy advice on the Medicare program. A board-certified nephrologist, Dr. Jaffery is member of numerous professional organizations including the American Association for Physician Leadership and the American Society of Nephrology and is a fellow of the American College of Physicians. jjaffery@uwhealth.org
Twitter: @jbjaffery

RAVI KALHAN, MD, MS
Dr. Ravi Kalhan is director of the Northwestern Asthma and Chronic Obstructive Pulmonary Disease (COPD) Program and associate division chief for clinical and translational research in the Division of Pulmonary and Critical Care Medicine. He additionally serves as co-director of the Center for Education and Career Development in the Northwestern University Clinical and Translational Sciences (NUCATS) Institute and as the director of the NUCATS Masters of Science in Clinical Investigation program.

Dr. Kalhan's research focus is in respiratory epidemiology. He leads large-scale epidemiologic cohort studies focused on lifecourse transitions from respiratory health to chronic lung disease. Central to this work is a framework that attempts to identify the components of ideal respiratory health, and thereby shifts the focus of the respiratory community from secondary to primary prevention of lung disease.

Dr. Kalhan attended college at Brown University in Providence, RI, where he majored in modern American history. He subsequently entered medical school at Case Western Reserve University School of Medicine and completed his internal medicine residency at the Hospital of the University of Pennsylvania. He then came to Chicago where he pursued his fellowship training in Pulmonary and Critical Care Medicine at Northwestern Memorial Hospital, formal training in clinical epidemiology, and has been on the Northwestern faculty since 2006. rkalhan@northwestern.edu
Twitter: @rkalhan

ELLA KAZEROONI, MD, MS
Dr. Ella Kazerooni's work in lung cancer screening research, coverage and implementation is extensive. She serves as the vice chair of the National Comprehensive Cancer Network (NCCN) Lung Cancer Screening panel, served as the inaugural chair of the American College of Radiology (ACR) Lung-RADS committee and chairs the ACR’s Lung Cancer Screening Registry (LCSR), and worked towards the ACR Designated Lung Cancer Screening program under the CT accreditation program. These efforts are focused on bringing quality lung cancer screening to high risk individuals and reduce the mortality from the #1 cancer—killer. Most recently, Dr. Kazerooni was named the inaugural chair of the American Cancer Society’s National Lung Cancer Roundtable. With a master's degree in Clinical Research Design & Statistical Analysis, Dr. Kazerooni's research focuses on the development and evaluation of advanced imaging technologies applied to the heart and lungs, including lung cancer screening, coronary artery and aortic disease, pulmonary embolism, and diffuse lung diseases. Her work in clinical and translational research earned her the University of Michigan Medical School's prestigious Clinical and Health Services Researcher of the Year award. ellakaz@med.umich.edu
Twitter: @ellakaz
**STEPHEN LAM, MD, FRCP**

*Dr. Stephen Lam* is an interventional pulmonologist at BC Cancer, professor of medicine at the University of British Columbia (UBC) and distinguished scientist, the Leon Judah Blackmore chair in lung cancer research and MDS-Rix endowed director of translational lung cancer research at the BC Cancer Research Institute. He is the medical director of the lung cancer screening program in British Columbia. He is an expert advisor of the Canadian Partnership Against Cancer and chairs the Partnership’s Pan-Canadian Lung Cancer Screening Network. He was the recipient of the International Association for the Study of Lung Cancer (IASLC) Joseph Cullen Award for life-time scientific achievements in lung cancer prevention research and the 2020 Doctors of BC Terry Fox Medal. Dr. Lam received his medical training at the University of Toronto. He joined the UBC Faculty of Medicine in 1979 and BC Cancer in 1984.

slam2@bccancer.bc.ca

---

**CHRISTOPHER LATHAN, MD, MS, MPH**

*Dr. Christopher Lathan’s* primary research interests are centered on the effects of race, class, and access to care in cancer outcomes, including racial disparities in lung cancer treatment, differences in access to precision medicine by race and social class and equitable distribution of new treatment across vulnerable populations. As Chief Clinical Access and Equity Officer at Dana-Farber Cancer Institute, Dr. Lathan aims to bridge the gap between research efforts in disparities and the realities of patient care by developing interventions to increase access to high quality care, developed in part through community engagement. He remains a clinical oncologist focusing on lung cancer patients and is the founding director of the Cancer Care Equity Program at the Dana-Farber Cancer Institute, a clinical outreach program that aids in the diagnosis and treatment of cancer for patients at Federally Qualified Health Centers. He is also the associate medical director of the Dana-Farber Cancer Institute Network, with a focus on the accessibility of clinical trials.

christopher_lathan@dfci.harvard.edu

---

**PAUL LIMBURG, MD, MPH**

*Dr. Paul Limburg* holds the academic rank of professor of medicine in the Mayo Clinic College of Medicine and serves as chief medical officer for Screening at Exact Sciences. Dr. Limburg has served on several enterprise-wide committees at Mayo Clinic, including the Management Team and the Clinical Practice Committee.

With respect to his research activities, Dr. Limburg is principal investigator for the Cancer Prevention Network, an international, multicenter clinical trial consortium funded by the US National Cancer Institute. His primary research interests include screening innovation, cancer chemoprevention, and molecular epidemiology. To date, Dr. Limburg has published over 130 peer-reviewed articles and 19 book chapters.

Dr. Limburg has received numerous awards and honors throughout his career, including a Cancer Prevention Laurel for Dedication to Community Programs from the Cancer Research and Prevention Foundation of America, a Career Development Award from the National Cancer Institute, and the Karis Award from Mayo Clinic. Dr. Limburg is widely recognized for his clinical, research, and leadership contributions in the field of cancer prevention.

plimburg@exactsciences.com

Twitter: @limburg_paul

Linkedin: www.linkedin.com/in/paul-limburg
ERIK LIUM, PhD

Dr. Erik Lium is the president of Mount Sinai Innovation Partners (MSIP) and chief commercial innovation officer for the Mount Sinai Health System. Dr. Lium is responsible for advancing Mount Sinai’s research, instruction, and public service missions through strategic research partnerships with industry, the management, transfer and commercialization of Mount Sinai technologies, and fostering the development of start-ups to advance promising early-stage technologies.

Under Dr. Lium’s leadership and through Mount Sinai’s expansive network of industry partnerships and vast array of innovators in the fields of therapeutics, medical devices, diagnostics, and digital health, Mount Sinai has become a globally recognized leader in advancing commercialization of healthcare technologies to benefit patients and society.

Dr. Lium joined Mount Sinai as vice president of MSIP in 2014 and was named president in 2019. Earlier, he held positions at the University of California, San Francisco (UCSF), including assistant vice chancellor of innovation, technology and alliances; UCSF principal investigator for the Bay Area National Science Foundation I-Corps node; and assistant vice chancellor of research. He also served as founder and president of LabVelocity Inc., an information services company focused on accelerating research and development in the life sciences.

Dr. Lium earned his PhD in Cellular, Molecular and Biophysical Studies at Columbia University and pursued post-doctoral training at UCSF.

erik.lium@mssm.edu

DAVID M. MANNINO, MD, FCCP, FERS

Dr. David Mannino is currently the medical director at the COPD Foundation. He has a long history of research and engagement in respiratory health.

He graduated from Jefferson Medical College (now Sidney Kimmel College of Medicine) in Philadelphia in 1981 and went on to complete his internship and residency at Lankenau Hospital in Philadelphia. He completed his fellowship in pulmonary medicine at West Virginia University School of Medicine/National Institute for Occupational Safety and Health in Morgantown, West Virginia. He joined the Centers for Disease Control and Prevention’s (CDC) Air Pollution and Respiratory Health Branch in 1991 until his retirement from the US Public Health Service in 2004. While at CDC, he helped to develop the National Asthma Program and led efforts on the Surveillance Reports that described the US burden of Asthma (1998) and COPD (2002).

After his retirement from CDC in 2004, Dr. Mannino joined the faculty at the University of Kentucky where he was involved both clinically in the College of Medicine and as a teacher, researcher, and administrator in the College of Public Health. He served as professor and chair in the Department of Preventive Medicine and Environmental Health from 2012 to 2017, with a joint appointment in the Department of Epidemiology.

In 2004, Dr. Mannino helped to launch the COPD Foundation, where he served as a board member from 2004 through 2015, chairman of the Medical and Scientific Advisory Committee from 2010 through 2015, and chief scientific officer from 2015 to 2017.

Dr. Mannino has over 350 publications and serves as an associate editor or Editorial Board member for the following journals: American Journal of Respiratory and Critical Care Medicine, Chest, Thorax, European Respiratory Journal, and the Journal of the COPD Foundation. He was also a coauthor of the Surgeon General’s Report on Tobacco in 2008 and 2014.

dmmann2@email.uky.edu
Twitter: @dmmannino
LinkedIn: www.linkedin.com/in/davidmannino/
ANITA McGLOTHLIN
Steering Committee Member, Quantitative Imaging Workshop

Anita McGlothlin joined the GO2 Foundation for Lung Cancer in 2018 as the director of Economics and Health Policy. Founded by patients and survivors, it is their mission to save, extend and improve the lives of those vulnerable, at-risk and diagnosed with lung cancer. Within this role, Ms. McGlothlin advances lung cancer screening and care through health policy, regulatory and coverage and reimbursement efforts.

Ms. McGlothlin works closely with Patient and Outreach Services and Science and Research programs to advance the Foundation’s mission through the development and implementation of health policies. With over twenty years of experience in economics and health policy and having led low dose CT lung cancer screening national coverage efforts with radiology in her prior role, Ms. McGlothlin has a unique interest in reducing patient access barriers and increasing the lung cancer screening and survival rates.

With a focus in public policy, Ms. McGlothlin continues her work in lung cancer patient advocacy by serving on the National Lung Cancer Roundtable (NLCRT) Policy Action Task Group, and formerly served as their vice-chair.

amcglothlin@go2foundation.org
Twitter: @GO2Foundation

JAMES L. MULSHINE, MD
Founder and Steering Committee Chair, Quantitative Imaging Workshop

Dr. James Mulshine is a professor at Rush University where he has served as associate provost and vice president for research as well as acting dean of the Graduate College. Prior to joining Rush University in 2005, Dr. Mulshine was at the National Cancer Institute (NCI) for 25 years, where he was on the research faculty. Internationally recognized as an expert on lung cancer, Dr. Mulshine’s research concentrates on application of quantitative CT to enable robust, efficient early lung cancer detection. Beginning in 2003, Dr. Mulshine—in cooperation with the Prevent Cancer Foundation®—established the Quantitative Imaging Workshop. He has been awarded 12 patents and has more than 330 scientific and medical publications. Dr. Mulshine is on numerous editorial boards, as well as national and international scientific and foundation advisory boards, including serving as vice chairman and scientific director of the Prevent Cancer Foundation®. He has received numerous national and international recognition awards related to the impact of his research efforts on early cancer management most recently including the Aeschylus Award from the Bonnie J. Addario Foundation.

james_l_mulshine@rush.edu

MARY PASQUINELLI, DNP, APRN, FNP-BC, CTTS
James L. Mulshine, MD, National Leadership Award 2021 Recipient

Dr. Mary Pasquinelli is a nurse practitioner specializing in lung cancer, lung cancer screening, and pulmonary nodule management at the University of Illinois Hospital and Health Science System in Chicago (UI Health). She holds a Doctorate of Nursing Practice, a Master of Science degree with a Family Nurse Practitioner specialty, and a bachelor’s degree in Psychology.

Dr. Pasquinelli’s clinical care and research is focused on lung cancer, health disparities, and decreasing barriers of care to improve clinical outcomes. She is responsible for the development and management of the UI Health Lung Screening Program and has improved the navigation of newly diagnosed lung cancer patients into treatment.

Dr. Pasquinelli also serves as principal investigator or co-investigator on multiple grants and research protocols, and she has authored several publications related to race and sex disparities in lung cancer screening. She is an active member with the National Lung Cancer Roundtable (NLCRT) Policy Task Force and the International Association for the Study of Lung Cancer (IASLC) Early Detection and Screening Committee.

mpasqu3@uic.edu
Twitter: @MaryPasquinelli

In partnership with American Lung Association
Nicholas Petrick, PhD

**Dr. Nicholas Petrick** is deputy director for the Division of Imaging, Diagnostics and Software Reliability at the Center for Devices and Radiological Health, US Food and Drug Administration (FDA) and is a member of the FDA Senior Biomedical Research Service. The Division of Imaging, Diagnostics and Software Reliability Division conducts regulatory research in medical imaging physics and image analysis techniques to optimizing medical image interpretation. Dr. Petrick received his PhD from the University of Michigan in Electrical Engineering-Systems and is a Fellow of the Americana Institute of Medical and Biomedical Engineering and the International Society for Optics and Photonics (SPIE). His current research focuses on quantitative imaging, medical machine learning and the development of robust assessment methods for a range of medical imaging hardware systems and medical machine learning tools.

nicholas.petrick@fda.hhs.gov
LinkedIn: [www.linkedin.com/in/nicholas-petrick-904a0510](https://www.linkedin.com/in/nicholas-petrick-904a0510)

---

Heather Pierce, JD, MPH

**Heather Pierce** is the senior director for science policy and regulatory counsel at the Association of American Medical Colleges (AAMC) and the director of policy for the AAMC Center for Health Justice. She serves as the AAMC's leader for scientific regulatory issues in areas such as human subject protections; clinical research; conflicts of interest; research data-sharing; evidence-based regulation; diagnostic test development; and collaborations between industry, government, and academia in biomedical research. Ms. Pierce is the subject matter expert for the AAMC's Forum on Conflict of Interest in Academe and for Convey®, the AAMC's global financial interest disclosure system.

During the COVID-19 pandemic, she has led the association on issues related to COVID-19 testing and regulatory aspects of vaccine and treatment development.

Ms. Pierce currently serves on the board of directors for the Association for the Accreditation of Human Research Protection Programs and was previously the chair of the board of directors of Public Responsibility in Medicine and Research, where she has been a regular contributor to in-person programs and webinars for over a decade. She has published articles and commentaries in Nature, Science, the New England Journal of Medicine, JAMA, and the American Journal of Bioethics. She has served on committees, working groups, and task forces of national organizations, including the National Academies of Sciences, Engineering, and Medicine; The Pew Charitable Trusts; and the National Dialogue for Healthcare Innovation.

She received her law degree from New York University School of Law and her master's degree in public health focusing on health law from Boston University.

hpierce@aamc.org
Twitter: @HeatherHPierce

---

Bruce S. Pyenson, FSA, MAAA

**Steering Committee Member, Quantitative Imaging Workshop**

**Bruce Pyenson** is principal and consulting actuary at Milliman, Inc., in New York. In his more than 30 years at Milliman, he has consulted to almost every sector of healthcare, including accountable care organizations (ACOs), employers, advocacy groups, insurers, and the biotechnology industry. Many of his projects involve integrating analytics from financial, clinical, and operational models.

In recent years, client projects have included the cost-benefit of lung cancer screening, the cost advantage of CT colonography, the impact of proposed changes to Medicare Part D, foundational work on healthcare value, marginal cost analyses using risk adjustment methodologies, feasibility analyses for ACOs, restructuring of disease management processes, and actuarial cost/benefit evaluations for pharmaceutical manufacturers.

Mr. Pyenson is a Fellow of the Society of Actuaries and a member of the American Academy of Actuaries. He is a commissioner on MedPAC, the Medicare Payment Advisory Commission, which advises Congress. He is an adjunct clinical associate professor of New York University’s College of Global Public Health and a member of the Institute for Healthcare Delivery Science at the Mount Sinai Health System. He serves on the Board of the International Early Lung Cancer Action Program. He was on the board of the Health Project (Koop Awards) from 2010–2016.

bruce.pyenson@milliman.com
Twitter: @bruce-pyenson
LinkedIn: [www.linkedin.com/in/brucepyenson](https://www.linkedin.com/in/brucepyenson)
ANTHONY P. REEVES, PhD
Dr. Anthony Reeves is a professor in the School of Electrical and Computer Engineering and director of the Vision and Image Analysis Lab (VIA) at Cornell University. He also holds an adjunct faculty position in the Department of Radiology at the Icahn School of Medicine at Mount Sinai, New York City. His research program is on computer methods for analyzing and making quantitative measurement on digital images with a primary focus on biomedical applications. Collaboration with the Early Lung Cancer Action Program (ELCAP) has resulted in computer methods for the detection and analysis of pulmonary nodules in low-dose CT images and the development of the web-based image-management system, SIMBA, which facilitates clinical studies, observer studies, and algorithm research. This work has been extended to the automated computer-aided diagnosis of diseases within the chest. Other ongoing collaborative projects for the VIA Lab are related to multidimensional image analysis including fuel droplet combustion measurement, sphere tracking in microgravity, hip dysplasia in a canine model, and analysis of single cells form optical CT 3D microscope images. Dr. Reeves has participated in the National Cancer Institute’s Lung Image Database Consortium (LIDC), and the Radiological Society of North America (RSNA) Quantitative Image Biomarkers Alliance (QIBA); his research program has received support from the National Institutes of Health, National Science Foundation and National Aeronautics and Space Administration (NASA).
reeves@cornell.edu

ALBERT RIZZO, MD, FCCP, FACP, FAASM
Steering Committee Member, Quantitative Imaging Workshop
Dr. Albert Rizzo, as chief medical officer for the American Lung Association, is the organization’s senior medical authority. Dr. Rizzo has long been a key medical advisor to the Lung Association, a member of the Lung Cancer Expert Medical Advisory Panel and a leading media spokesperson. In his role as Chief Medical Officer, Dr. Rizzo plays a key role in multiple areas of our mission, including the Lung Association’s Lung Helpline, research, and the Awards and Grants program as well as advocacy, communications, development and health promotions. Dr. Rizzo is responsible for ensuring that the Lung Association is always using the best science and medicine to formulate and deliver on our mission.

Dr. Rizzo is a member of Christiana Care Pulmonary Associates at the Christiana Care Health System in Newark, Delaware. He is board certified in internal medicine, pulmonary, critical care and sleep medicine and is a clinical assistant professor of medicine at Thomas Jefferson University Medical School in Philadelphia where he obtained his medical degree and completed his residency in internal medicine.

albert.rizzo@lung.org
Twitter: @arizzomd
LinkedIn: www.linkedin.com/in/albert-rizzo-bb15068/

RAÚL SAN JOSÉ ESTÉPAR, PhD
Steering Committee Member, Quantitative Imaging Workshop
Dr. Raúl San José Estépar is co-director of the Applied Chest Imaging Laboratory at Brigham and Women’s Hospital and associate professor of Radiology at Harvard Medical School. His laboratory focuses on novel computational imaging applications for image-based biomarker discovery to empower epidemiological and genetic studies and provide novel surrogate targets for drug discovery and clinical trial development. His group supports the image analytics of multiple Federal and Industry sponsored investigations serving as imaging core for COPDGene, the Framingham Heart Study Pulmonary Research Center, the CARDIA Lung Study and, more recently, the American Lung Association (ALA) Lung Health Cohort. Dr. San José Estépar is the original developer and chief architect of the Chest Imaging Platform, an open-source software platform for CT-based lung phenotyping. His research has made significant contributions to the quantitative study of pulmonary vascular remodeling and the subtyping and modeling of parenchymal lung injury. His current research interests are focused on artificial intelligence approaches to enable multiscale integration of imaging and molecular information using deep learning, synthetic lung functional imaging from single energy CT, and image-based outcomes prediction models in chronic lung diseases.

Dr. San José Estépar received his PhD in Telecommunications Engineering from the University of Valladolid, Spain, where he specialized in signal processing applied to medical image analysis and conducted his post-doc in the Surgical Planning Laboratory, Brigham and Women’s Hospital. He has been faculty at Harvard Medical School since 2006. He has co-authored over 200 peer-reviewed manuscripts, and he is currently the principal investigator of several National Institutes of Health awards and industry sponsored studies. He is a member of the Fleischner Society, and he is actively involved in disseminating quantitative approaches for better healthcare delivery. He has been on the steering committee for the Quantitative Imaging Workshop since 2015. Dr. San José Estépar is also the founder and scientific advisor of Quantitative Imaging Solutions, a healthcare technology company that translates image-based AI solutions and modeling to detect and predict lung diseases.
rsanjose@bwh.harvard.edu
In partnership with

KATHRYN H. SCHMITZ, PhD, MPH, FACSM, FTOS, FNAK

Dr. Kathryn Schmitz is a Distinguished Professor of Public Health Sciences at the Pennsylvania State University’s College of Medicine and the Penn State Cancer Institute. She is a clinical trialist who has led many exercise trials. Dr. Schmitz also has translated her work into clinical practice and served as president of the American College of Sports Medicine (ACSM). Dr. Schmitz has chaired the Global Exercise Is Medicine Governing Committee, and she is the founder of the Moving Through Cancer Initiative of the ACSM.

Dr. Schmitz has published more than 260 peer-reviewed scientific papers (h-index 62) and has had $25 million dollars in funding for her research since 2001. She was the lead author of the first ACSM Roundtable on Exercise for Cancer Survivors. In March 2018, Dr. Schmitz co-chaired an International Multidisciplinary ACSM Roundtable on Exercise and Cancer Prevention and Control. The physicians, outpatient rehabilitation specialists, researchers and exercise professionals in the room broadly agreed it is time for exercise oncology to go prime time. The question is how. Dr. Schmitz’s professional mission is to answer that question.

drkatieschmitz@gmail.com
Twitter: @ftaftercancer
Instagram: @fitnessaftercancer

MARIO SILVA, MD, PhD

Dr. Mario Silva graduated in Radiology at the University of Parma and completed a research fellowship in Cardio-Pulmonary Imaging at the Beth Israel Deaconess Medical Center in Boston, Harvard Medical School, Massachusetts. Dr. Silva is an active researcher in the field of thoracic imaging, including thoracic oncology. His main scientific interests are early diagnosis of lung cancer by screening with low-dose CT and the evolving scenario of medical treatment of pulmonary malignancies. During the 2020 pandemic of SARS-CoV-2 he served in the task force for the development of integrated clinics-radiological management of respiratory triage, at the University Hospital of Parma. He has authored or co-authored over 100 peer-reviewed articles published in international scientific journals, numerous abstracts at international congresses, and published book chapters on thoracic imaging. Dr. Silva is editor of the book Tumor Dissemination Pathways – The Thorax by Springer. He is reviewer for various international scientific journals. He is the “Chest” Lead Section Editor of the European Journal of Radiology, moreover he serves as “Chest” Associate Editor of the British Journal of Radiology, and “Diagnostic Imaging” Section Editor of the Tumori Journal. He is currently assistant professor in Radiology at the University of Parma (Italy).
mario.silva@unipr.it

EMANUELA TAIOLI, MD, PhD

Dr. Emanuela Taioli joined Mount Sinai as a professor of population health and science, as well as a professor of thoracic surgery in 2015. She was also named the director of the Institute for Translational Epidemiology, and as director of the Center for the Study of Thoracic Diseases Outcomes. Currently, Dr. Taioli also serves as the associate director for Population Science at The Tisch Cancer Institute (TCI) and co-leads the Cancer Prevention and Control Program. Before assuming her position at Mount Sinai, Dr. Taioli was the Chief of Epidemiology for the Northwell Health System at Hofstra School of Medicine. She established herself as a pioneer in pooling large datasets and establishing the first international pooled analysis of studies on gene-environment interaction, which lead to the formation of large consortia investigating cancer outcomes on an international level.

Among her most important contributions are those to the field of cancer prevention, including the study of cancer risk factors in healthy populations, cancer predisposing factors, hormone metabolism and genetic susceptibility to environmental exposure. She is a well-recognized expert in cancer survivorship and the effect of lifestyle changes on the risk for cancer recurrence and the development of new secondary cancers. Moreover, she has worked extensively on health disparities, access to care in minority populations, and chronic diseases prevention in the underserved.

Dr. Taioli has contributed to over 300 scientific and medical studies, in addition to several book chapters. She has collaborated with other scientists and medical experts across the nation, and has become recognized internationally for her work on cancer prevention and identifying cancer risk factors. Dr. Taioli works closely with doctors, particularly for lung cancer detection, screening and developing treatment plans.
emanuela.taioli@mountsinai.org

EMANUELA TAIOLI, MD, PhD

Dr. Emanuela Taioli joined Mount Sinai as a professor of population health and science, as well as a professor of thoracic surgery in 2015. She was also named the director of the Institute for Translational Epidemiology, and as director of the Center for the Study of Thoracic Diseases Outcomes. Currently, Dr. Taioli also serves as the associate director for Population Science at The Tisch Cancer Institute (TCI) and co-leads the Cancer Prevention and Control Program. Before assuming her position at Mount Sinai, Dr. Taioli was the Chief of Epidemiology for the Northwell Health System at Hofstra School of Medicine. She established herself as a pioneer in pooling large datasets and establishing the first international pooled analysis of studies on gene-environment interaction, which lead to the formation of large consortia investigating cancer outcomes on an international level.

Among her most important contributions are those to the field of cancer prevention, including the study of cancer risk factors in healthy populations, cancer predisposing factors, hormone metabolism and genetic susceptibility to environmental exposure. She is a well-recognized expert in cancer survivorship and the effect of lifestyle changes on the risk for cancer recurrence and the development of new secondary cancers. Moreover, she has worked extensively on health disparities, access to care in minority populations, and chronic diseases prevention in the underserved.

Dr. Taioli has contributed to over 300 scientific and medical studies, in addition to several book chapters. She has collaborated with other scientists and medical experts across the nation, and has become recognized internationally for her work on cancer prevention and identifying cancer risk factors. Dr. Taioli works closely with doctors, particularly for lung cancer detection, screening and developing treatment plans.
emanuela.taioli@mountsinai.org
RUTH TAL-SINGER, PhD

Dr. Ruth Tal-Singer, president and chief scientific officer at the COPD Foundation, is internationally recognized as an innovative, patient-focused, and highly analytical health care leader and clinical scientist with extensive R&D experience. She has a proven history of successfully leading international public and private partnerships and non-profit organizations through critical advancements and progress of clinical trials and large international observational cohorts. Dr. Tal-Singer is adept at building and maintaining global partnerships between pharma, patients, academia, advocacy groups and governments. She has authored hundreds of peer-reviewed articles, including highly cited scientific publications that reported important insights on COPD (h-index 68). Since taking the helm of the COPD Foundation, Dr. Tal-Singer has been a powerful advocate for visionary thinking and transformative approaches to putting the patient at the heart of research, building internal medical and scientific expertise, and catalyzing action in partnership with like-minded global organizations. Recent initiatives include the formation of COPD360Net®, the COPD Foundation’s digital health and therapeutics development accelerator network, and the Community Engagement Committee (CEnCo).

rtalsinger@copdfoundation.org
Twitter: @rtalsinger1
LinkedIn: www.linkedin.com/in/r-tal-singer-phd

GEORGE R. WASHKO, MMSc, MD

Dr. George Washko is a physician at Brigham and Women’s Hospital (BWH). He is also an associate professor of medicine at Harvard Medical School.

He received his medical degree from Georgetown University School of Medicine. Dr. Washko then completed a residency in internal medicine at Beth Israel Deaconess Medical Center, followed by a fellowship in pulmonary and critical care medicine disease in the Harvard Combined Fellowship for Pulmonary and Critical Care Medicine. He is board certified in critical care medicine and pulmonary disease.

Dr. Washko is a National Institutes of Health-funded investigator in chronic obstructive pulmonary disease (COPD), specifically focusing his work in imaging and quantitative image analysis. He is also one of the co-primary investigators for the National Heart, Lung and Blood Institute-funded American Lung Association Lung Health Cohort (ALA-LHC). This study will enroll 4,000 millennials and ask them to undergo detailed characterization to understand the earliest manifestations of loss of lung health. Dr. Washko’s lab leads multiple investigator-initiated studies and serves as an analytics core for federal and industry sponsored national and international clinical investigations. The breadth of these collaborations has provided investigators in Dr. Washko’s lab the opportunity to identify and develop areas of interest that enable their transition to independence.

gwashko@bwh.harvard.edu

DAVID YANKELEVITZ, MD

Steering Committee Member, Quantitative Imaging Workshop

Dr. David Yankelevitz is a professor of Radiology and the director of the Lung Biopsy Service at the Icahn School of Medicine. He is a world-recognized expert on Fine Needle Aspirations (FNAs) of lung nodules and he has developed one of the largest biopsy practices in the United States.

Also a researcher, Dr. Yankelevitz’s main academic interest is in the evaluation of treatments for early-diagnosed lung cancer; and he has been the co-principal investigator of the Initiative for Early Lung Cancer Research on Treatment (IELCART) since its inception in 2015. As part of that program, and in order to advance the diagnosis and treatment of lung cancer, one of his contributions was to develop the idea of evaluating lung nodule growth rates to create benchmark measurements that assess cancer risk. In addition to the IELCART research, Dr. Yankelevitz has, for the past 20 years, been a co-principal investigator of the International Early Lung Cancer Action Program (i-ELCAP) – a lung cancer screening study which, to date, has screened over 80,000 people in 10 countries around the world; and he has been principal investigator on four National Cancer Institute (NCI) grants.

Dr. Yankelevitz has co-authored over 300 peer-reviewed articles and book chapters, and he has trained 40 Research Fellows in thoracic imaging. Prior to joining the faculty at Mount Sinai in 2010, he was a professor of Radiology at Weill Cornell Medical College in New York City. Dr. Yankelevitz received his MD from SUNY Downstate Medical Center.

david.yankelevitz.mountsinai.org
ROWENA YIP, MPH

Rowena Yip is a senior biostatistician in the Department of Diagnostic, Molecular and Interventional Radiology at the Icahn School of Medicine at Mount Sinai. She is also an affiliated member of the Biostatistics Shared Resource Facility at the Tisch Cancer Institute at Mount Sinai. Ms. Yip’s research focuses on the application of statistical and epidemiological methods to critical diagnostic and therapeutic topics involved in lung cancer screening and treatment. Her recent work involves assessing the determinants of aggressive lung cancers, optimization of nodule management in CT lung cancer screening, and development of lung cancer risk prediction models. Ms. Yip is currently a PhD candidate, and she holds an MPH in biostatistics.

rowena.yip@mountsinai.org

JAVIER J. ZULUETA, MD, FCCP

Dr. Javier Zulueta is professor of medicine at the Icahn School of Medicine and chief of the Pulmonary, Critical Care and Sleep Medicine Division at Mount Sinai Morningside Hospital in New York, NY. Previously, he served as associate professor and 20-year director of Pulmonary Medicine at the Clinica Universidad de Navarra, the teaching hospital of Spain’s University of Navarra School of Medicine. He started in 2000 and led until 2020 the longest ongoing lung cancer screening trial in Europe as part of the I-ELCAP consortium. Dr. Zulueta's research interests include lung cancer screening, diagnosis of lung nodules, and the relationship between lung cancer, COPD and emphysema.

Dr. Zulueta also recently served as chief medical officer of VisionGate. Inc. He is a member of the Committee on Prevention and Early Detection of Lung Cancer of the International Association for the study of Lung Cancer (IASLC), a Fellow of the American College of Chest Physicians, and member of the American Thoracic Society, American Respiratory Society, European Respiratory Society and Spanish Association of Pulmonary Medicine and Thoracic Surgery. He has authored more than 100 publications in peer-reviewed journals and has been an invited lecturer at more than 100 international conferences.

Dr. Zulueta received his medical doctorate from the Universidad Complutense in Madrid, Spain. His specialization in pulmonary and critical care medicine was earned at Tufts Medical Center, Tufts University School of Medicine in Boston, MA.

javier.zulueta@mountsinai.org
Twitter: @DrZulueta
LinkedIn: www.linkedin.com/in/javier-zulueta